story of the week
Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)
Clin. Cancer Res 2019 Mar 18;[EPub Ahead of Print], NC Turner, ML Telli, HS Rugo, A Mailliez, J Ettl, EM Grischke, LA Mina, J Balmaña, PA Fasching, SA Hurvitz, AM Wardley, C Chappey, AL Hannah, ME RobsonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.